托鲁地文拉法辛治疗抑郁症的药理作用与临床评价  

Pharmacological effects and clinical evaluation of toludesvenlafaxine in the treatment of depression

作　　者：李宇蒙 杜小雨 邱博[2] 吴惠珍 LI Yumeng;DU Xiaoyu;QIU bo;WU Huizhen(Graduate School of Hebei Medical University,Shijiazhuang 050017,Hebei,China;Department of Parmacy,Hebei General Hospital,Hebei Key Laboratory of Clinical Pharmacy,Shijiazhuang 050051,Hebei,China)

机构地区：[1]河北医科大学研究生学院,河北石家庄050017 [2]河北省人民医院药学部,河北省临床药学重点实验室,河北石家庄050051

出　　处：《中国临床药理学与治疗学》2025年第3期419-426,共8页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：河北省自然科学基金青年基金项目(H2020307020)。

摘　　要：抑郁症是常见的精神类疾病,目前抗抑郁药物治疗存在疗效不佳和药物相关安全性问题。托鲁地文拉法辛作为新型三重再摄取抑制剂(triple reuptake inhibitor,TRIs/SNDRIs),在5-羟色胺(5-hydroxytryptamine/serotonin,5-HT)和去甲肾上腺素(norepinephrine,NE)基础上增加多巴胺(dopamine,DA)再摄取抑制作用,实现多靶点协同治疗,同时减少5-HT/NE相关药物不良反应。本文对托鲁地文拉法辛的基本介绍、临床前研究、临床有效性和安全性等进行综述,以为抑郁症的治疗提供更多思路和选择。Depression is a common mental disease.At present,there are poor efficacy and drugrelated safety problems in antidepressant treatment.Toludesvenlafaxine,as a new triple reuptake inhibitor(TRIs/SNDRIs),increases the inhibitory effect of dopamine(DA)reuptake on the basis of serotonin(5-HT)and norepinephrine(NE),achieves multi-target synergistic therapy and reduces 5-HT/NE-related adverse drug reactions.This article reviews the basic introduction,preclinical research,clinical efficacy and safety of toludesvenlafaxine,in order to provide more ideas and options for the treatment of depression.

关 键 词：抑郁症 托鲁地文拉法辛 5-HT/NE/DA三重再摄取抑制剂 

分 类 号：R749.4[医药卫生—神经病学与精神病学]